From a previous post:
Read More »I knew nothing of Donbass or Palestine until after I started this blog. In fact, I was hesitant to blog about Palestine at first. It wasn’t until after I learned more about Islam that I started looking at the Middle East. Before that, I was into Christopher Hitchens and followed Robert Spencer and Pamela Geller. Charlie Kirk, from TP USA, and Michelle Malkin even followed me on Twitter. Now, I don’t care for any of them.
A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD).
The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an expedited review given that the agency previously designated the psychedelic as a breakthrough therapy.
FDA Weighs New Application To Approve MDMA As First-Ever Psychedelic Medicine For PTSD
H/T: The Most Revolutionary Act
The MAPS Public Benefit Corporation is subsidiary of Multidisciplinary Association for Psychedelic Studies. MAPS was founded by Rick Doblin.*
Related:
Read More »
Ms. Cat’s Chronicles 